Research Update

AstraZeneca PLC
23 April 2007



AstraZeneca announces decision to discontinue collaboration with AtheroGenics
regarding AGI-1067


AstraZeneca today announced that it has decided to terminate the License and
Collaboration Agreement with AtheroGenics, Inc. (Nasdaq: AGIX), regarding
AGI-1067.


AGI-1067, an investigational anti-atherosclerotic agent, was studied in the
ARISE (Aggressive Reduction of Inflammation Stops Events) phase III clinical
outcomes trial in patients with coronary artery disease (CAD).    The initial
results from ARISE were announced by AtheroGenics on 19 March 2007 and presented
at the American College of Cardiology on 27 March 2007.


The decision to terminate the collaboration was reached following a full
analysis of the AGI-1067 product profile in the context of the terms and
conditions of the License and Collaboration agreement.


Provisions for the impairment of intangible assets and associated close down
costs of $83m to be taken in 1Q 2007.



The ARISE study

ARISE was a double-blind, randomised, placebo controlled study which involved
more than 6,000 patients with coronary artery disease from over 250 centres in
Canada, South Africa, the UK and the US.  The study was designed to evaluate the
additional benefits of adding AGI-1067 to current standard of care therapies, on
several outcomes due to coronary vascular events such as death, heart attack,
stroke, revascularisation and hospital admission for unstable angina.



AstraZeneca

AstraZeneca is a major international healthcare business engaged in the
research, development, manufacture and marketing of prescription pharmaceuticals
and the supply of healthcare services. It is one of the world's leading
pharmaceutical companies with healthcare sales of $26.47 billion and leading
positions in sales of gastrointestinal, cardiovascular, neuroscience,
respiratory, oncology and infection products. AstraZeneca is listed in the Dow
Jones Sustainability Index (Global) as well as the FTSE4 Good Index.





                                     -Ends-



23 April 2007



Media enquiries:
Patricia O'Connor, Tel: [phone]

Edel McCaffrey, Tel: [phone]
Steve Brown, Tel: [phone]

Investor Relations:
Mina Blair, Tel: [phone]
Jonathan Hunt, Tel: [phone]
Karl Hard, Tel: [phone]
Jorgen Winroth, Tel: [phone]
Ed Seage, Tel: [phone]






                      This information is provided by RNS
            The company news service from the London Stock Exchange